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Prognostic Signiﬁcance of Strain Doppler
Imaging in Light-Chain Amyloidosis
Jun Koyama, MD,*‡ Rodney H. Falk, MD*†
Boston, Massachusetts; and Matsumoto, Japan
O B J E C T I V E S To clarify the prognostic value of strain and strain rate imaging in light-chain (AL)
amyloidosis.
B A C KG ROUND Myocardial strain and strain rate Doppler imaging are objective measurements
that may detect regional subtle myocardial functional abnormalities in patients with amyloidosis.
METHOD S We prospectively examined 119 consecutive, untreated patients with biopsy-proven AL
amyloidosis. The mean values of tissue velocity, strain, and strain rate were calculated from the basal,
mid, and apical left ventricular (LV) multiple walls in apical 2- and 4-chamber views. The prognostic value
of these parameters was compared with standard 2-dimensional echocardiographic and Doppler
measurements of transmitral and pulmonary venous ﬂow.
R E S U L T S Seventy patients had cardiac involvement deﬁned as the mean value of LV wall thickness
greater than 12 mm. Thirty-two patients (27%) (including 22 proven cardiac deaths) died during a mean
follow-up period of 285  136 days. No echocardiographic or Doppler features differentiated patients
with cardiac involvement without congestive heart failure (CHF) from noncardiac amyloid group other
than the pre-deﬁned wall thickness and LV end-diastolic and end-systolic diameters. On the other hand,
strain rate and strain imaging clearly detected differences of longitudinal LV myocardial deformation
among 3 groups (noncardiac involvement group, cardiac amyloidosis without CHF group, and cardiac
amyloidosis with CHF group). Univariate analysis showed that strain rate, strain, and tissue velocity
values were statistically signiﬁcant predictors of outcome at most of the sites. Multivariate analysis
showed that the mean LV basal strain was the only independent predictor of both cardiac and overall
deaths.
CONC L U S I O N S Among patients with AL amyloidosis, the mean basal strain, a measure of
longitudinal LV function, was a powerful predictor of clinical outcome and was superior to standard
2-dimensional echocardiographic, Doppler ﬂow measurements, and simple tissue velocity indexes. (J Am
Coll Cardiol Img 2010;3:333–42) © 2010 by the American College of Cardiology Foundation
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334rimary light-chain (AL) amyloidosis is a plasma
cell dyscrasia associated with the deposition of
immunoglobulin-derived amyloid in multiple or-
gans. In the heart, this results in an infiltrative
ardiomyopathy, with increased left ventricular
LV) wall thickness, normal or decreased LV cavity
ize, and congestive heart failure (CHF) (1–5).
ardiac involvement is a major determinant of
rognosis of AL amyloidosis, and previous studies
ave attempted to correlate echocardiographic ab-
ormalities with survival (2,4).
LV wall thickness 15 mm, reduced LV systolic
unction (2), shortened deceleration time, and in-
reased early-to-late diastolic filling ratio of trans-
itral flow have all been reported as predictors of
eath in cardiac amyloidosis (4).
Regional strain (change in length per unit length)
nd strain rate (SR), the temporal derivative of
train (6), have been validated in experimental
odels and are sensitive markers of systolic myo-
ardial function (7). We have previously shown
hat, using these techniques, systolic dysfunction
can be demonstrated in cardiac amyloid-
osis when it is not apparent by other
echocardiographic techniques (8). We
have further shown that the cyclic varia-
tion of integrated backscatter at the ven-
tricular posterior wall, a parameter of in-
trinsic myocardial contraction (9), is a
predictor of clinical outcome that is supe-
rior to standard echocardiographic/
oppler flow indexes in AL amyloidosis (10). We
herefore hypothesized that strain and SR may be
dditional tools for defining prognosis in this dis-
ase, and we performed this study in order to clarify
he prognostic value of strain/SR Doppler analysis
n a consecutive series of patients with primary
AL) amyloidosis. We also sought to compare the
rognostic value of strain/SR Doppler with that of
he standard 2-dimensional echocardiography and
oppler (2,4).
E T H O D S
wo hundred ten consecutive patients with biopsy-
roven AL amyloidosis were examined at the Bos-
on University Amyloidosis Treatment and Re-
earch Center between April 23, 2001, and March
2, 2002. The diagnosis of amyloidosis was made
hen a biopsy specimen of an involved organ
emonstrated typical Congo Red birefringence un-
er polarized light. AL amyloidosis was confirmed
rey the finding of a monoclonal protein in the serum Dr urine and/or a monoclonal population of plasma
ells in the bone marrow when evaluated by immu-
ohistochemistry (11). Patients with non-AL amy-
oidosis were not enrolled. Twenty-three patients
ith poor echocardiographic images (n 10), atrial
brillation (n 5), history of hypertension (n 7),
r significant valvular disease (n  1) were ex-
luded. We also excluded 68 patients who had
ndergone intravenous melphalan therapy with
tem cell transplantation before the initial echocar-
iographic examination as this therapy has been
hown to prolong survival, but its effect on echo-
ardiographic indexes is not known. Thus, the final
opulation consisted of 119 patients, all of whom
ad evidence of a plasma cell dyscrasia.
All patients underwent a physical examination by
cardiologist (R.H.F.) with particular emphasis on
he presence or absence of signs and symptoms of
HF. CHF was defined as dyspnea on exertion,
ssociated with orthopnea, paroxysmal nocturnal
yspnea, or a chest radiographic appearance of heart
ailure and/or the presence of elevated jugular ve-
ous pressure. Echocardiograms were reviewed by 2
eaders to determine the presence or absence of
ardiac involvement, defined as a mean value of LV
hickness 12 mm in the absence of hypertension,
alvular heart disease, or criteria for LV hypertro-
hy on the electrocardiogram (ECG) (3,12). Sev-
nty patients met the echocardiographic criteria for
ardiac involvement, and 49 patients had no fea-
ures of cardiac amyloidosis. The latter group was
efined as group 1 (noncardiac amyloid). Of the 70
atients with cardiac amyloidosis, 37 had prior or
urrent evidence of CHF. These patients were
efined as group 3 (CHF [] group) and the
emaining 33 were defined as group 2 (CHF []
roup). Follow-up data were obtained from corre-
pondence with the patient, with his or her family,
nd/or from the referring physician. Death data and
ate of death were also ascertained through an
n-line Social Security database. The protocol was
pproved by the institutional review board, and
ritten informed consent was obtained from each
atient.
ltrasound examination and measurements. Ultra-
ound examinations were performed with a com-
ercially available echocardiographic machine
Vivid Five System, Vingmed-General Electric,
ilwaukee, Wisconsin). Standard M-mode mea-
urements of the LV were made. Transmitral flow
elocity pattern and pulmonary venous flow were
ecorded as described previously (8,10). Analysis ofB B R E V I A T I O N S
N D A C R O N YM S
HF congestive heart failu
V left ventricular
R strain rateoppler flow was performed using dedicated soft-
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335are (Echopac 6.3.6, GE Vingmed Ultrasound).
hree consecutive beats were measured and aver-
ged for each measurement. Peak velocities of early-
E) and late-filling (A) waves, duration of A-wave,
he E/A ratio, and deceleration time of the E-wave
ere measured from transmitral flow velocities, and
he peak velocities of the systolic (S), diastolic (D),
nd A waves, duration of A-wave, and the D/S ratio
ere also measured from pulmonary venous flow.
issue Doppler data acquisition. Apical 2- and
-chamber views were obtained (Fig. 1), and
-dimensional color tissue Doppler recordings were
ecorded during brief apnea after expiration at a
rame rate 97 to 132 frames per second (mean value
10 frames/s). Pulse repetition frequency was ad-
usted to avoid aliasing. The acquired raw data were
ransferred to a hard drive for offline analysis.
issue velocity, strain, and SR. Color 2-dimensional
igital data from 3 consecutive cardiac cycles were
nalyzed offline using software incorporated in the
ivid Five System (Echopac 6.3.6, GE Vingmed
ltrasound). The investigator performing the tissue
oppler, strain/SRI analysis (J.K.) did not know
hich patients had CHF. Sample volumes were
laced in the inner half of the myocardium to keep
he angle between the Doppler beam and the
ongitudinal shortening direction of the wall (or the
Figure 1. Sample Volume Positions and Analyzed Waveforms
(Left) Sample volume position in apical 2- and 4-chamber views. Sa
and anterior walls at the base, mid-, and apical ventricular levels. (R
peak late diastolic strain rate; Atv  peak late diastolic tissue veloc
tissue velocity; Ssr  peak systolic strain rate; Stv  peak systolic tissueirection of endocardium) as small as possible (at
east 30°). Measurements were made at the center
f each basal, mid-, and apical LV segment at the
eptum, lateral, inferior, and anterior walls (Fig. 1).
R is equal to the spatial myocardial velocity
radient expressed by the equation: SR  (v[r] 
[rr])/r (where r  distance along ultrasound
eam, v  tissue velocity). Strain is calculated by
ombining the SR values over a given time interval
s described previously (6,7). An offset (r) of 10.8 or
1.1 mm was used in all studies. Tissue velocity
TV), strain, and SR curves were acquired from the
ame sample volume in the same image at each site
nd the mean values were calculated from 3 cardiac
ycles (Fig. 1). Peak systolic strain was determined
s the difference in strain measured from the onset
f the QRS complex to the nadir of the strain
racing. For SR, peak systolic SR, peak early dia-
tolic SR, and peak late diastolic SR were measured.
V waves were obtained from the same sample
olumes, and peak systolic, early diastolic, and late
iastolic TV were measured. Values at each wall are
eported separately and were also averaged to give a
ean basal, mid- and apical value.
Inter- and intraobserver variability were assessed
y measuring 18 datasets of averaged mean basal,
id- and apical value derived from 6 patients
e volumes were placed in the septum and the lateral, inferior,
t) Measurements of tissue velocity, strain rate, and strain. Asr 
sr  peak early diastolic strain rate; Etv  peak early diastolicmpl
igh
ity; Evelocity.
r
p
e
i
p
m
S
S
a
I
a
t
c
g
a
s
d
v
p
d
t
s
o
s
a
s
t
v
M
t
p
r
i
E
m
a
o
R
T
s
T
l
g
d
2
t
d
h
g
i
s
2
v
t
P
t
p
t
T
v
a
e
S
a
f
s
s
g
b
I
d
systolic wave velocity; TMF
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 4 , 2 0 1 0
A P R I L 2 0 1 0 : 3 3 3 – 4 2
Koyama and Falk
Strain Doppler and Prognosis in Amyloidosis
336andomly selected from each group, for a total of 18
atients. The second measurements were done sev-
ral months after the first measurements for both
nter- and intraobserver variability. Results are ex-
ressed as the linear regression between the 2
easurements and as the percent error.
tatistics. All data are expressed as mean  SD.
tatistical analyses were done with a commercially
vailable software program (Stat View 5.0, SAS
nstitute Inc., Cary, North Carolina). Differences
mong 3 group characteristics were assessed with
he chi-square test for categorical variables, and
omparisons of continuous variables among 3
roups were made using the 1-way or factorial
nalysis of variance with repeated measures for
egment and wall, followed by the Scheffé test. A
ifference was considered significant when the p
alue was 0.05.
The median value of variables was used to divide
atients into 2 groups when survival free of cardiac
eath and overall survival were estimated using
he Kaplan-Meier method (13). To determine a
uitable cutoff value, we constructed the receiver-
Echocardiographic and Doppler Characteristics (n  119)
Group 1
(n  49)
Group 2
(n  33)
Group 3
(n  37)
59.0 9.8 56.5 11 59.4 10.4
21/28 23/10 19/18
75 13 78 13 87 16*
121 21 115 17 109 15†
72 10 72 10 69 10
10.2 1.2 14.5 1.8 ‡ 15.8 2.7‡§
49.3 6.5 44.6 6.3 * 41.2 5.0‡
28.9 6.3 25.8 5.2 † 29.8 4.7§
42.7 7.9 41.3 8.6 28.2 9.6‡
41.5 7.5 45.0 9.2 46.6 6.9†
0.66 0.14 0.68 0.21 0.86 0.20‡¶
0.67 0.16 0.69 0.22 0.38 0.21‡
168 32 159 29 150 27
1.08 0.51 1.15 0.72 2.71 1.15‡
199 50 205 56 166 82§
0.52 0.19 0.46 0.18 0.25 0.14‡
0.45 0.14 0.46 0.18 0.58 0.17*§
0.23 0.08 0.24 0.07 0.20 0.10
145 26 132 27 133 39
1.03 0.68 1.22 0.97 2.95 1.57‡
†p  0.05 versus group 1; ‡p  0.0001 versus group 1; §p  0.05 versus group
.0001 versus group 2; ¶p  0.001 versus group 2.
ave velocity; BP  blood pressure; D  peak diastolic wave velocity; DT 
k early diastolic wave velocity; LAD left atrial diameter; LVDd left ventricular
Ds  left ventricular end-systolic diameter; LVFS  left ventricular fractional
entricular thickness at end diastole; PVF  pulmonary venous ﬂow; S  peak
 transmitral ﬂow.perator characteristic curve, and took values where eensitivity is as equal as possible to specificity. We
lso measured the area under the curve, which is a
ummary measure of performance determined by
he receiver-operator characteristic curve (14). Uni-
ariate analyses were followed by a log-rank test.
ultivariate analysis to determine the relative con-
ribution of variables was examined by Cox’s pro-
ortional hazards regression model (15). A stepwise
egression analysis was performed to investigate the
ndependence of mean LV basal strain from tissue
velocity and the deceleration time of the trans-
itral E-wave. A 0.05 level of significance was
pplied to determine whether variables were added
r removed from the model (15).
E S U L T S
wo-dimensional echocardiographic and Doppler mea-
urements. Clinical characteristics are shown in
able 1. Systolic blood pressure was significantly
ower and heart rate was significantly higher in
roup 3 than in the other 2 groups. No echocar-
iographic or Doppler features differentiated group
from group 1 other than the pre-defined wall
hickness and LV end-diastolic and end-systolic
iameters (Table 1), whereas patients in group 3
ad more abnormalities than either of the other 2
roups. Left atrial diameter was significantly greater
n group 3 than in group 1, and the LV fractional
hortening was smaller in group 3 than in the other
groups. Patients in group 3 showed greater peak E
elocity, peak E/A ratio, peak D-wave velocity, and
he peak D/S ratio of pulmonary venous flow.
atients in group 3 also showed smaller values in
he peak transmitral A-wave, peak S velocity of
ulmonary venous flow, and deceleration time of
ransmitral E-wave than in the other 2 groups.
V, SR, and strain imaging. Peak values of tissue
elocity, strain, and SR measured at each segment
re shown in Figures 2A to 2C, and mean values for
ach wall are shown in Figure 2D (Table 2).
egmental values at the base, mid-ventricle, and
pex trended in the same direction and were there-
ore pooled for statistical analysis of prognostic
ignificance. As we have previously shown (8), peak
ystolic TV did not differ between group 1 and
roup 2 at any site, but was lower in group 3 at the
ase and mid-LV than in either of the other groups.
n contrast to the indexes of systolic TV, peak early
iastolic TV at the LV base was statistically differ-Table 1. Patients and
Age (yrs)
Male/female
Heart rate (beats/min)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Mean LVThd (mm)
LVDd (mm)
LVDs (mm)
LVFS (%)
LAD (mm)
TMF-E (m/s)
TMF-A (m/s)
TMF-A duration (ms)
TMF-E/A
TMF E-DT (ms)
PVF-S (m/s)
PVF-D (m/s)
PVF-A (m/s)
PVF-A duration (ms)
PVF-D/S
*p  0.01 versus group 1;
2 (by Scheffé test); p  0
A  peak atrial ﬁlling w
deceleration time; E pea
end-diastolic diameter; LV
shortening; LVThd  left vnt among all 3 groups. Whereas peak late diastolic
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337V was significantly lower at all 3 segments in
roup 3 compared with either of the other groups,
V imaging could not distinguish between groups 1
nd 2. In contrast to TV imaging, SR and strain
maging clearly detected differences of longitudinal
V myocardial deformation among all 3 groups
oth in systole and early diastole at the base and
id-LV. The SR at late diastole distinguished
etween groups 1 and 2 only at the mid-LV.
rognostic value of echocardiogram/Doppler and tis-
ue Doppler indexes. Of the 119 patients, 32 died
uring a mean follow-up period of 285  136 days
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0.001 versus group 2, §§p  0.0001 versus group 2.censored periods range from 199 to 510 days), and i2 of the 32 deaths (68.8%) were either sudden or
ue to CHF. Patients with heart failure showed
ignificantly poorer prognosis than the other 2
roups (Fig. 3, upper panels). Univariate analysis
howed that strain, SR, and TV values were statis-
ically significant predictors of outcome at most of
he sites, although apical values tended not to differ
mong groups. The stepwise regression analysis
howed that the mean LV basal strain, TVI-E-
pex, and the deceleration time of transmitral
-wave were independent predictors. Multivariate
nalysis of these 3 parameters showed that the only
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338rom any cause or cardiac death was basal systolic
train (Table 3).
The receiver-operator characteristic analysis for
he total patient group indicated that a basal strain
alue of 13.0% was the most suitable cutoff value
o predict all death, and a strain value of 12.0%
est predicted cardiac death (Fig. 3, middle panels).
ecause CHF is a strong predictor of adverse
utcome (Fig. 3, upper panels), we also analyzed the
roups without CHF (groups 1 and 2) separately
rom group 3 (Fig. 4). In the groups without CHF,
receiver-operator characteristic curve– derived
utoff value of strain at the basal LV of 13.0%
redicted cardiac death (p  0.047). This value is
imilar to that of the total group, but the value was
tatistically less robust. In group 3, all of whom had
eart failure by definition, strain was still capable of
dding prognostic value; a cutoff basal strain of
4.6% best predicted death from any cause,
imilar to the value for cardiac death (4.4%).
eproducibility. The inter- and intraobserver vari-
bilities of are shown in Table 4. The reproducibil-
Table 2. Strain, Strain Rate, and Tissue Doppler Score Characte
Group 1 (CV%
(n  49)
Tissue velocity imaging (TVI) (cm/s)
TVI-S-Base 4.80 1.13 (2
TVI-S-Mid 3.23 0.95 (2
TVI-S-Apex 1.74 0.70 (4
TVI-E-Base 5.10 1.60 (3
TVI-E-Mid 3.75 1.38 (3
TVI-E-Apex 2.20 0.96 (4
TVI-A-Base 5.20 1.84 (3
TVI-A-Mid 3.67 1.70 (4
TVI-A-Apex 1.63 0.99 (6
Strain rate imaging (SRI) (1/s)
SRI-S-Base 1.72 0.46 (2
SRI-S-Mid 1.44 0.37 (2
SRI-S-Apex 1.38 0.29 (2
SRI-E-Base 1.72 0.65 (3
SRI-E-Mid 1.41 0.49 (3
SRI-E-Apex 1.47 0.59 (4
SRI-A-Base 1.64 0.64 (3
SRI-A-Mid 1.48 0.60 (4
SRI-A-Apex 1.24 0.71 (5
Strain (%)
Strain-Base 18.3 4.9 (27
Strain-Mid 16.6 5.0 (30
Strain-Apex 14.4 3.9 (27
*p  0.0001 versus group 1, †p  0.0001 versus group 2, ‡p  0.001 versus grou
#p  0.05 versus group 2 (by Scheffé test).
CV  coefﬁcient of variation (%); other abbreviations as in Table 1.ty of strain was better than that of the other warameters, and the measurements of TV and SR at
he apex were less reproducible than at the basal and
id-LV.
ffect of treatment on prognosis. Thirty-four pa-
ients received high-dose intravenous melphalan
herapy with stem cell transplantation, and the
emaining 85 had oral regimens. These treatments
ere based on the best judgment of evaluating
hysicians after echocardiographic assessment. As
hown in Figure 5, there was no statistical difference
etween intravenous and oral regimens in both
ll-cause and cardiac death.
I S C U S S I O N
ardiac involvement in AL amyloidosis is the
ommonest cause of death, and therefore, an objec-
ive method to assess the cardiac prognosis in
ntreated patients is desirable (2,4,5,10,16,17). We
reviously showed that, despite echocardiographic
vidence of amyloid infiltration, longitudinal sys-
olic function in AL amyloidosis appeared normal
cs
Group 2 (CV%)
(n  33)
Group 3 (CV%)
(n  37)
4.36 1.19 (27) 2.95 1.12 (38)*†
3.03 0.90 (30) 2.44 0.89 (36)‡#
1.83 0.85 (46) 1.40 0.58 (41)#
4.07 1.31 (32) 3.07 1.32 (43)*#
3.00 1.27 (42)¶ 2.71 1.35 (50)¶
2.05 1.07 (52) 1.95 0.97 (50)
4.60 1.85 (40) 1.51 1.18 (78)*†
3.28 1.65 (50) 1.21 0.87 (72)*†
1.50 0.91 (61) 0.70 0.40 (57)*§
1.48 0.62 (42) 0.70 0.40 (57)*†
1.13 0.29 (26)‡ 0.78 0.41 (53)*§
1.39 0.34 (24) 0.99 0.45 (45)*†
1.44 0.63 (44) 0.67 0.50 (75)†
1.09 0.42 (39) 0.77 0.35 (45)*
1.23 0.44 (36) 1.09 0.57 (52)
1.54 0.79 (51) 0.59 0.57 (97)*†
1.23 0.76 (62)# 0.44 0.31 (70)*†
1.26 0.79 (63) 0.44 0.31 (70)*†
13.9 5.0 (36)‡ 6.5 4.3 (66)*†
12.2 3.9 (32)* 7.7 3.9 (51)*§
13.2 4.1 (31) 10.4 4.4 (42)*#
§p  0.001 versus group 2, p  0.01 versus group 1, ¶p  0.05 versus group 1,risti
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339HF (18). We subsequently evaluated myocardial
train/SR imaging in these patients, and demon-
trated that this technique can detect longitudinal
ystolic dysfunction even before the onset of heart
ailure (8). In the present study, we have shown that
R imaging is not only useful for demonstrating
ystolic dysfunction, but is also a powerful prognos-
ic indicator of survival.
Several non-Doppler–derived echocardiographic
arameters such as increased mean LV wall thick-
ess, decreased fractional shortening, and LV in-
ow filling variables have been reported to be
mportant independent predictors of cardiac mor-
ality in small series of patients with cardiac amy-
oidosis (2,4,10,16), although there is some incon-
istency of these findings between studies (10,17).
yclic-dependent variation of myocardial inte-
rated backscatter, a parameter considered to cor-
elate with changes in intrinsic myocardial contrac-
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Figure 3. Overall Survival and Survival Free of Cardiac Death in
(Upper), overall survival and survival free of cardiac death in each g
Small vertical lines in graphs represent censor time. Group 1, nonc
3, cardiac involvement with CHF. (Middle), receiver-operator charac
cardiac death). (Lower), overall survival and survival free of cardiac
119).ility (9), was found to be the most sensitive oarker predicting poor outcome among multiple
ltrasonic variables in amyloidosis, including LV
nflow filling indexes (10). Although this finding
upported the concept that sensitive markers of
ntrinsic myocardial contraction may be predic-
ors of clinical outcome in patients with AL
myloidosis, that study did not include tissue
oppler, strain, or SR.
In the present investigation, regional variations in
train and SR were noted both in patients with
ormal echocardiograms and those with evidence of
ardiac amyloidosis. The values in our group 1
atients demonstrate a slightly lesser degree of
pical than basal strain and SR, and are very similar
o the slight regional variation found by Andersen
nd Poulsen (19) in normal subjects. Basal strain
as superior to traditional diastolic Doppler flow
arameters and was also a stronger predictor of
utcome than early diastolic measurements of TV
oup I
oup II
oup III
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th in patients with light-chain (AL) amyloidosis in all groups (n Gr
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operator characteristic cutoff value of 4.6% best predicted all death and
%FS  percent fractional shortening; other abbreviations as Tables 1 and 2.
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340eart failure was associated with a very poor prog-
osis, an analysis of basal strain limited to this
roup demonstrated its independent prognostic
alue.
A cardiovascular magnetic resonance study
emonstrated a characteristic pattern of global
ate gadolinium enhancement with a dominant
ubendocardial distribution that matches the
ransmural distribution of amyloid protein (20).
t can be speculated that subendocardial domi-
ant deposition of amyloid protein reduces sub-
ndocardial contraction, which contributes to
ongitudinal LV shortening and could lead to
ongitudinal LV dysfunction and poor cardiac
rognosis (21).
The patients were treated by various therapies
fter the echocardiography study, based on clinical
ssessment of their disease, including high-dose
hemotherapy. Although high-dose chemotherapy
ith autologous stem cell transplant has been
hown to be beneficial in some patients with AL
myloidosis (22), there are data to suggest that less
ggressive therapies (as received by some patients) are
qually effective in high-risk cardiac patients (23).
rom our results, we are not convinced that stem cell
herapy would necessarily have had an additional
mpact on outcome in cardiac amyloidosis—a group
f patients known for a very upfront mortality with
tem cell therapy.
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Figure 4. Analysis in Groups Without CHF (1  2) and Group With
Receiver-operator characteristic curve–derived cutoff value of 13.0% preTable 3. Univariate Mantel-Cox and Multivariate Cox Proportional Hazards Analysis
(Log-Rank Test, n  119)
All-Cause Death
(n  32)
Cardiac Death
(n  22)
Chi-Square p Value Chi-Square p Value
Univariate*
%FS (39) 5.00 0.0254 8.38 0.0038
LVThdm (12.6) 9.34 0.0022 10.00 0.0015
TMF-E/A (1.12) 6.33 0.0118 9.12 0.0025
TMF-DT (186) 6.31 0.0120 5.74 0.0166
PVF-D/S (1.13) 11.40 0.0007 10.60 0.0011
Strain-Base (13.28) 9.31 0.0023 13.60 0.0002
Strain-Mid (11.69) 5.08 0.0241 10.30 0.0013
SRI-S-Mid (1.11) 9.99 0.0016 9.16 0.0025
SRI-A-Mid (0.97) 6.81 0.0091 8.44 0.0037
SRI-A-Apex (0.85) 7.57 0.0059 8.70 0.0032
TVI-S-Base (4.14) 5.75 0.0165 4.95 0.0260
TVI-S-Apex (1.56) 8.90 0.0029 6.66 0.0099
TVI-E-Base (4.26) 5.16 0.0232 7.87 0.0050
TVI-E-Mid (3.20) 7.34 0.0067 6.64 0.0100
TVI-E-Apex (2.1) 10.40 0.0013 9.62 0.0019
TVI-A-Base (4.02) 5.11 0.0237 7.83 0.0051
Multivariate*
Strain-Base (13.28) 5.210 0.0225 7.022 0.0081
TMF-DT (186) 3.95 0.0468 3.088 0.0789
TVI-E-Apex (2.1) 1.39 0.2385 2.210 0.1371
*Median value.4.4% best predicted cardiac death.
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341tudy limitations. Strain Doppler measurements
re angle dependent (6,7), and the angle between
he ultrasound beam and LV wall must be small.
ecause of curvature of the apex, the measure-
ent of apical LV strain may be artifactually
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Figure 5. Overall Survival and Survival Free of Cardiac Death in
Overall survival and survival free of cardiac death in high-dose in
group (n  34) and oral melphalan therapy group (n  85). The
ing physicians after echocardiographic evaluation. There was no
Table 4. Intraobserver and Interobserver Variability of TV, SR, a
Systole
Intraobserver Interobserver Intrao
Tissue velocity
Base R2 0.970 0.988 0
SE (cm/s) 0.045 0.026 0
Mid R2 0.968 0.966 0
SEE (cm/s) 0.044 0.045 0
Apex R2 0.895 0.966 0
SEE (cm/s) 0.073 0.046 0
Strain rate
Base R2 0.983 0.995 0
SEE (1/s) 0.032 0.017 0
Mid R2 0.962 0.976 0
SEE (1/s) 0.051 0.039 0
Apex R2 0.902 0.930 0
SEE (1/s) 0.090 0.076 0
Strain
Base R2 0.996 0.998
SEE (%) 0.015 0.012
Mid R2 0.996 0.998
SEE (%) 0.015 0.009
Apex R2 0.996 0.992
SEE (%) 0.017 0.023
SEE  standard error of the estimate; SR  strain rate; TV  tissue velocity.cardiac death.elated to Doppler alignment, and this may be the
eason why the basal, not apical parts of the LV
eem to indicate prognostic relevance. However,
his should not have affected the results of the
tudy. With the method used, a limitation of SR
elphalan 
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342s a relatively poor signal-to-noise ratio. To
inimize this effect we measured and averaged 3
ardiac cycles.
We did not randomize patients into high-dose
ntravenous or oral regimens group after echocar-
iographic assessment; there is insufficient evidence
o suggest that therapy choice would have modified
atients’ prognosis.
O N C L U S I O N S
his study demonstrates that systolic basal strain
s a predictor of clinical outcome in patients with
L amyloidosis, and is superior to Doppler flowography in patients with AL (primary)
17. Tei C, Dujardin
Kyle RA, Tajik AJ,t has an additive prognostic value even when
eart failure is present. This finding may help to
elect patients with AL amyloidosis for treatment,
articularly when high-dose intravenous melphalan
ith autologous stem cell transplantation is consid-
red, as this therapy, although successful in produc-
ng a hematologic remission in a significant propor-
ion of patients, is associated with a high prevalence
f cardiac complications that limit its utility in
otentially high-risk patients with cardiac involve-
ent from their disease (22,23).
eprint requests and correspondence: Dr. Jun Koyama, De-
artment of Cardiovascular Medicine, Shinshu University
raduate School of Medicine, Asahi 3-1-1, Matsumoto,measurements and to diastolic TV or SR indexes. Japan 390-8621. E-mail: jkoyama@shinshu-u.ac.jp.1
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